Wingspan Offers eTMF Readiness Assessment
Wingspan Technology now offers an eTMF Readiness Assessment program to help sponsors and CROs assess their level of readiness for implementing eTMF.
Wingspan Technology now offers an eTMF Readiness Assessment program to help sponsors and CROs assess their level of readiness for implementing eTMF. Completion of the Readiness Assessment will help organizations to learn about best practices, identify gaps, plan resource needs, and move towards risk-based decision making. The assessment can be tailored to best support an organization based on its size, previous experience, partnering approach, and more.
The process begins with a workshop that focuses on reviewing lessons learned from relevant case studies and discussing key elements of eTMF readiness with a cross-functional team. Wingspan’s experts facilitate the discussion, emphasizing the impact that decisions made in early project phases will have in optimizing processes, increasing efficiency and decreasing regulatory risk. The organization then completes a detailed questionnaire covering 11 key aspects of eTMF readiness. Wingspan analyzes the responses and produces a report interpreting the results, benchmarking the organization against industry wherever possible, and provides recommendations for areas of emphasis and return on investment.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
